Moderna's (MRNA) COVID-19 Vaccine Gets FDA Panel's Backing

·4-min read

Moderna, Inc. MRNA announced that the FDA’s Vaccines and Related Biological Products Advisory Committee has voted in favor of FDA granting an emergency use authorization (EUA) to its mRNA-based coronavirus vaccine candidate, mRNA-1273. From the panel, 20 members voted in support of providing the EUA, while there was no vote against it. The same committee had voted 17-4 recommending Pfizer PFE/BioNTech’s BNTX mRNA-based vaccine, BNT162b2. One member abstained during both advisory committee meetings.

We note that a recommendation for EUA was expected from the advisory committee as a briefing document released by the FDA before the meeting mentioned that mRNA-1273 was safe and effective in preventing COVID-19. The FDA is likely to follow advisory committee’s recommendation and Moderna may get an EUA in a day or two.

The recommendation was based on the totality of scientific evidence shared by Moderna, including data from the pivotal phase III COVE study evaluating mRNA-1273 in adult patients. The candidate demonstrated an encouraging efficacy rate of 94.1% during primary efficacy analysis as well as full protection against severe COVID-19 cases. The press release stated that the majority of local solicited adverse events occurred within the first one to two days after injection and remained for a median of one to two days.

 A National Institutes of Health-appointed independent Data Safety Monitoring Board will monitor all participants in the phase III study for two years after the second dose, to assess long-term protection and safety.

Moderna’s shares have skyrocketed 620.8% so far this year compared with the industry’s rise of 8.4%.

The company has started evaluating mRNA-1273 in adolescent patients aged 12 years or more. It plans to generate sufficient data by mid-2021 to support regulatory filings, seeking emergency authorization/approval for use of mRNA-1273 in adolescents. The company also has plans to initiate one surveillance study for evaluating the candidate in pregnant women and two other surveillance studies — active follow-up for safety and real-world effectiveness study.

The company is ready to ship 20 million doses to the U.S. government by the end of this year following the potential EUA. The company has signed an agreement to deliver another 180 million doses of mRNA-1273 to the U.S. government during the first half of 2021. The U.S. government has the option to purchase additional 300 million doses of mRNA-1273. The company has built enough manufacturing capacity to deliver 1 billion doses across the globe in 2021. The company is also focusing on the efficient distribution of the vaccine. The vaccine can remain stable at standard refrigerator temperatures of 2° to 8°C for 30 days. It now added that local transport can be included, which can distribute the vaccine under controlled conditions in a liquid state at 2-8°C.

Pfizer/BioNTech, have received emergency use approval for their vaccine in at least six countries including the United States and the United Kingdom. However, conditional marketing authorization requests for both candidates are under review in Europe. Extraordinary meetings for assessing marketing authorization application for BNT162b2 and mRNA-1273 have been scheduled on Dec 21, 2020 and Jan 6, 2021, respectively. Moderna has several other regulatory applications under review across different countries and also multiple supply agreements in place.

Meanwhile, AstraZeneca AZN /Oxford University’s potential vaccine candidate, AZD1222 was, on average, about 70% effective in preventing COVID-19, per interim data released from late-stage studies. J&J and CureVac’s COVID-19 vaccine candidates are also in late-stage development and study data are expected next year.

Moderna, Inc. Price

Moderna, Inc. Price
Moderna, Inc. Price

Moderna, Inc. price | Moderna, Inc. Quote

Zacks Rank

Moderna currently carries a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AstraZeneca PLC (AZN) : Free Stock Analysis Report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
Moderna, Inc. (MRNA) : Free Stock Analysis Report
 
BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting